Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Post infarct heart failure: What to do in addition to ACE inhibition

  • 14 Accesses


ACE (angiotensin converting enzyme) inhibitors are revolutionizing the management of heart failure and are now earning themselves a place in the early treatment of post myocardial infarction (MI) patients who have evidence of left ventricular (LV) dysfunction or, more modestly, evidence of infarct expansion. The aims of ACE inhibitor therapy are to control symptoms, if any, and to improve prognosis. For these indications, they are impressive. Nonetheless, they are not a panacea. Post MI patients face a variety of threats, not least from progression of their underlying ischemic disease, and they should not be denied prognostically advantageous interventions, such as beta-blockers and aspirin. Moreover, ACE inhibitor monotherapy may not be the best management for heart failure itself. The role of other additive agents should not be dismissed.

This is a preview of subscription content, log in to check access.


  1. 1.

    Norris RM, Caughey DE, Mercer CJ, Deeming LW, Scott PJ. Coronary prognostic index for predicting survival after recovery from acute myocardial infarction.Lancet 1970;2:485–487.

  2. 2.

    Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.Lancet 1988;1:255–259.

  3. 3.

    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS).N Engl J Med 1987;316:1429–1435.

  4. 4.

    Pfeffer MA, Braunwald E, Moye LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med 1992;327:669–677.

  5. 5.

    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med 1992;327:685–691.

  6. 6.

    Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction—results of the Cooperative New Scandinavian Enalapril Survival study II (CONSENSUS II).N Engl J Med 1992;327:678–684.

  7. 7.

    Ray SG, McAlpine HM, Morton JJ, Leckie B, Dargie HJ. The importance of the renin angiotensin system and the role of ACE inhibitors after myocardial infarction.Angiology 1991;42:268–272.

  8. 8.

    Higham PD, Adams PC, Murray A, Campbell RWF. Plasma potassium, serum magnesium and ventricular fibrillation: A prospective study.Q J Med 1993;86:609–617.

  9. 9.

    Nordrehaug JE, Johannessen KA, Van der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction.Circulation 1985;71:645–649.

  10. 10.

    Bigger JT, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ. Effect of digitalis treatment on survival after myocardial infarction.Am J Cardiol 1985;55:623–630.

  11. 11.

    Madsen EB, Gilpin E, Henning H, et al. Prognostic importance of digitalis after acute myocardial infarction.J Am Coll Cardiol 1984;3:681–689.

  12. 12.

    Ryan TJ, Bailey KR, McCabe CH, et al. The effects of digitalis on survival in high risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS).Circulation 1983;67:735–742.

  13. 13.

    Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG. Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment.Br Heart J 1989;61:529–539.

  14. 14.

    Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure.N Engl J Med 1983;309:748–756.

  15. 15.

    Massie BM, Berk MR, Brozena SC, et al. for the FACET Investigators. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and on angiotensin converting enzyme inhibitor therapy? Results of the flosequinan plus ACE inhibitor trial (FACET).Circulation 1993;88:492–501.

  16. 16.

    Flosequinan for chronic heart failure.Drug Ther Bull 1993;31:47–48.

  17. 17.

    Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction.Eur Heart J 1984;5:516–528.

  18. 18.

    The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction.N Engl J Med 1988;319:385–392.

  19. 19.

    Dunselman PHJM, Kuntze CEE, van Bruggen A, et al. Efficacy of felodipine in congestive heart failure.Eur Heart J 1989;10:354–364.

  20. 20.

    May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: A review of long-term trials.Prog Cardiovasc Dis 1982;24:331–352.

  21. 21.

    The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989;321:406–412.

  22. 22.

    The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.N Engl J Med 1992;327:227–233.

  23. 23.

    Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study.J Am Coll Cardiol 1992;20:1056–1062.

  24. 24.

    Burkart FF, Pfisterer M, Kiowski W, Follath F, Burckhardt D, Jordi H. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS).J Am Coll Cardiol 1990;16:1711–1718.

  25. 25.

    Pfisterer M, Kiowski W, Burckhardt D, Follath F, Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function.Am J Cardiol 1992;69:1399–1402.

  26. 26.

    Stewart RA, McKenna WJ, Poloniecki JD, et al. Prospective randomised double blind placebo controlled trial of low dose amiodarone in patients with severe heart failure and frequent ventricular extrasystoles.Br Heart J 1989;61:459.

  27. 27.

    Betablocker Heart Attack Trial Research Group. A randomized trial of propanolol in patients with acute myocardial infarction.JAMA 1982;247:1707–1714.

  28. 28.

    ISIS-2 (Second International Study of Infarct Survival (Collaborative Group). Randimised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction.Lancet 1988;2:349–360.

  29. 29.

    Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.J Am Coll Cardiol 1992;20:1549–1555.

  30. 30.

    Siu SC, Nidorf SM, Galambos GS, Weyman AE, Picard MH. The effect of late patency of the infarct-related artery on left ventricular morphology and regional function after thrombolysis.Am Heart J 1992;124:265–272.

  31. 31.

    Takeishi Y, Tonooka I, Kubota I, et al. Functional recovery of hibernating myocardium after coronary bypass surgery—does it coincide with improvement in reperfusion?Am Heart J 1991;122:665–670.

Download references

Author information

Correspondence to Professor R. W. F. Campbell.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Campbell, R.W.F. Post infarct heart failure: What to do in addition to ACE inhibition. Cardiovasc Drug Ther 8, 115–118 (1994). https://doi.org/10.1007/BF00877098

Download citation

Key Words

  • ACE inhibitor
  • heart failure
  • post-myocardial infarction
  • prognosis